Melatonin as an Antioxidant for Stroke Neuroprotection. Issue 5 (May 2016)

• Record Type: Journal Article
• Authors: Watson, Nate; Diamandis, Theo; Gonzales-Portillo, Chiara; Reyes, Stephanny; Borlongan, Cesar V.
• Is Part Of: Cell transplantation. Volume 25:Issue 5(2016)
• Page Start: 883
• Page End: 891
• Publication Date: 2016-05
• Subjects: Melatonin -- Pineal gland -- Antioxidant -- Neuroprotection -- Melatonin receptors -- Dementia; Cell transplantation -- Periodicals; Cell Transplantation; Cell transplantation; Electronic journals; Periodicals; Periodicals; 571.638
• DOI: 10.3727/096368915X689749
• Languages: English
• ISSNs: 0963-6897

Abstract

Melatonin ( N -acetyl-5-methoxytryptamine) is a hormone derived from the pineal gland that has a wide range of clinical applications. While melatonin was originally assessed as a hormone specializing in regulation of the normal circadian rhythm in mammals, it now has been shown to be an effective free radical scavenger and antioxidant. Current research has focused on central nervous system (CNS) disorders, stroke in particular, for potential melatonin-based therapeutics. As of now, the realm of potential therapy regimens is focused on three main treatments: exogenously delivered melatonin, pineal gland grafting, and melatonin-mediated stem cell therapy. All therapies contain both costs and benefits, and current research is still focused on finding the best treatment plan. While comprehensive research has been conducted, more research regarding the safety of such therapies is needed in order to transition into the clinical level of testing. Antioxidants such as traditional Chinese medicine, (–)-epigallocatechin-3-gallate (EGCG), and lavender oil, which have been used for thousands of years as treatment, are now gaining recognition as effective melatonin treatment alternatives. This review will further discuss relevant studies assessing melatonin-based therapeutics and provide evidence of other natural melatonin treatment alternatives for the treatment of stroke.